Myriad Genetics, Inc. (MYGN)

NASDAQ: MYGN · USD

$6.61

+0.32 (+5.1%)· Recorded snapshot

Market cap	632.2M
Revenue (ttm)	806.6M
Net income (ttm)	-112.6M
EPS (ttm)	-$1.20
Shares out	95.6M
Volume	2,003,558
Beta	1.64

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 806.6M
Net income (ttm): -112.6M
EPS (ttm): -$1.20
Market cap: 632.2M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Mantener

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-32.5

P25 n/aP50 n/aP75 n/a

ROIC-22

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All MYGN indicators

Market & fundamental data

Available fields

227

Groups with data

Currency

USD

Showing 227 of 227 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0000899923
Company name	Myriad Genetics, Inc.
Country	United States
Country code	US
CUSIP number	62855J104
Earnings date	2026-11-04
Earnings time	amc
Employees	2,700
Employees change	100
Employees growth	3.85%
Enterprise value	$727.5M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1991
In index	RUSSELL2000
Industry	Diagnostics & Research
IPO date	1995-10-05
Is primary listing	Yes
Is SPAC	No
ISIN number	US62855J1043
Last 10-K release date	2026-02-24
Last earnings date	2026-07-30
Last refreshed	2026-10-28
Last stock split date	2009-03-26
Last stock split type	Forward
Market cap	$632.2M
Market cap category	Small-Cap
Next earnings date	2026-11-04
Options	Yes
Price	$6.61
Price currency	USD
Sector	Healthcare
SIC code	2835
Stock price date	2026-10-28
Symbol	MYGN
U.S. state	Utah
Website	https://www.myriad.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-18.2%
EV/Sales	0.89x
FCF / EV yield	-1.02%
FCF yield	-1.18%
Forward EV/Sales	0.89x
Forward P/S	0.77x
Industry forward P/E	30.87x
Industry P/E	50.24x
P/B ratio	1.98x
P/OCF ratio	80.37x
P/S ratio	0.77x
Price / tangible book value	5.25x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-11.22%
EBITDA margin	-5%
Gross margin	68.83%
Operating margin	-11.22%
Pretax margin	-13.86%
Profit margin	-13.96%
Profit per employee	$-41,704
Revenue per employee	$298,741
ROA	-8.59%
ROA (5Y)	-5.91%
ROCE	-17.81%
ROE	-32.54%
ROE (5Y)	-26.44%
ROIC	-21.97%
ROIC (5Y)	-13.93%
SBC / revenue	3.56%
Tax / revenue	0.1%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	1
EPS growth years	0
Gross profit growth	-5.35%
Gross profit growth (Q)	-16.34%
Gross profit growth 3Y	5.15%
Gross profit growth 5Y	3.52%
Net income growth quarters	1
Net income growth years	0
OCF growth 10Y	-26.45%
Revenue growth	-3.16%
Revenue growth (Q)	-10.51%
Revenue growth (QoQ)	-4.84%
Revenue growth 10Y	0.86%
Revenue growth 3Y	4.89%
Revenue growth 5Y	4.02%
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-15M
Depreciation and amortization	$50.2M
EBIT	$-90.5M
EBITDA	$-40.3M
EPS	$-1.20
FCF per share	$-0.08
Financing cash flow	$47.2M
Free cash flow	$-7.3M
Free cash flow minus SBC	$-36M
Gross profit	$555.2M
Income taxes	$800,000
Investing cash flow	$-21.9M
Net borrowing	$64.9M
Net cash flow	$33.1M
Net income	$-112.6M
Operating cash flow minus SBC	$-21M
Operating income	$-90.5M
Revenue	$806.6M
Stock-based compensation	$28.7M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-0.58
Book value per share	$3.18
Debt / equity	0.69
Goodwill	$47.1M
Interest coverage	-5.52
Long-term assets	$349.9M
Long-term liabilities	$204.3M
Net cash (debt)	$-95.3M
Net cash / market cap	-15.4%
Net debt / equity	0.31
Piotroski F-Score	4
Property, plant and equipment	$158.9M
Shareholders' equity	$303.9M
Tangible book value	$117.8M
Tangible book value per share	$1.23
Total assets	$638.9M
Total cash	$115.2M
Total debt	$210.5M
Total liabilities	$335M
WACC	11.48%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	1.23
Current assets	$289M
Current liabilities	$130.7M
Current ratio	2.21
Inventory turnover	8.48
Net working capital	$50.4M
Quick ratio	1.72
Working capital	$158.3M
Working capital turnover	6.65

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-2.46%
Dividend yield	0%
Shareholder yield	-2.46%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-66.35%
10Y return CAGR	-10.32%
10Y total return	-66.35%
150-day SMA	$4.44
15Y price change	-69.62%
15Y return CAGR	-7.64%
15Y total return	-69.62%
1D price change	5.09%
1M price change	58.51%
1M total return	58.51%
1W price change	18.67%
1W total return	18.67%
1Y price change	-18.4%
1Y return CAGR	-18.41%
1Y total return	-18.4%
20-day SMA	$4.84
200-day SMA	$4.60
20Y price change	-50.82%
20Y return CAGR	-3.26%
20Y total return	-48.43%
3M price change	21.28%
3M total return	21.28%
3Y price change	-52.48%
3Y return CAGR	-21.96%
3Y total return	-52.48%
50-day SMA	$4.08
50-day SMA vs 200-day SMA	50under200
52-week high	$8.38
52-week high date	2025-11-03
52-week low	$2.74
52-week low date	2026-08-03
5Y price change	-78.43%
5Y return CAGR	-26.42%
5Y total return	-78.43%
6M price change	36.85%
6M total return	36.85%
All-time high	$69.00
All-time high date	2000-11-06
All-time low	$1.44
All-time low date	1998-08-31
Average true range (ATR)	$0.37
Average volume	3.2M
Beta (1Y)	-0.03
Beta (2Y)	1.2
Beta (5Y)	1.64
Change from 52-week high	-21.12%
Change from 52-week low	141.24%
Change from all-time high	-90.42%
Change from all-time low	359.67%
Change from open	6.27%
Day's gap	-1.11%
Dollar volume	$13.2M
High price	$6.64
Low price	$6.21
Monthly RSI	44.89
Open price	$6.22
Position in 52-week range	93.02%
Premarket change	0.32%
Premarket close	$6.29
Premarket price	$6.31
Premarket volume	2.3K
Previous close	$6.29
Price vs 150-day SMA	48.91%
Price vs 20-day SMA	36.51%
Price vs 200-day SMA	43.57%
Price vs 50-day SMA	61.97%
Relative volume	0.64
RSI	80.92
Sharpe ratio	0.2
Sharpe ratio (3Y)	-0.01
Sharpe ratio (5Y)	-0.17
Sortino ratio	0.33
Sortino ratio (3Y)	0.05
Sortino ratio (5Y)	-0.15
Volume	2M
Weekly RSI	64.35
YTD price change	7.48%
YTD total return	7.48%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	79.3M
Float percentage	82.89%
Shares change (QoQ)	1.17%
Shares change (YoY)	2.46%
Shares held by insiders	4.17%
Shares held by institutions	83.39%
Shares outstanding	95.6M
Short % of float	10.78%
Short % of shares	8.93%
Short ratio	4.1 days

Deeper analysis on MYGN

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this MYGN report

Is a complete MYGN research report available?

No complete published report is available for Myriad Genetics, Inc. (MYGN) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Myriad Genetics, Inc. (MYGN)

Price

Financial snapshot

Fair-value bridge

Latest news · MYGN

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All MYGN indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on MYGN

Frequently asked questions